The biotech is slashing a third of its workforce and more than half of its executive team in moves it called “necessary in ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

HHS will also centralize many functions that are currently spread out across the department, consolidating work involving ...

Clearance of Vykat unlocks what analysts anticipate will be a lucrative market opportunity for Soleno Therapeutics.

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis ...

A licensing deal with Jiangsu Hengrui Pharmaceuticals puts Merck in a competitive race to develop a medicine that targets a ...

The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...

Amvuttra’s clearance in a rare form of cardiomyopathy could help Alnylam turn a regular profit — if it can wrest control of a ...

The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several drugmakers.

The company plans to file next year for an accelerated clearance of its "exon-skipping" treatment, which would compete with one of Sarepta's medicines.

The company expects next quarter to read out initial data from its Heart-2 trial, which is testing a one-time treatment for ...

A young man treated with Elevidys died of acute liver failure. The case may give doctors pause before prescribing the ...